A metabolic marker–based diagnostic model for precancerous and malignant endometrial lesions in insulin-resistant PCOS women with sonographically suspected endometrial polyps - Scorecard - MDSpire
Advertisement
A metabolic marker–based diagnostic model for precancerous and malignant endometrial lesions in insulin-resistant PCOS women with sonographically suspected endometrial polyps
Clinical Scorecard: A Diagnostic Model Utilizing Metabolic Markers for Identifying Precancerous and Malignant Endometrial Lesions in Women with Insulin-Resistant PCOS and Suspected Endometrial Polyps
At a Glance
Category
Detail
Condition
Endometrial neoplasia in PCOS-IR patients
Key Mechanisms
Insulin resistance as a core pathophysiological driver
Target Population
Women with insulin-resistant PCOS and suspected endometrial polyps
Care Setting
Obstetrics and Gynecology
Key Highlights
Insulin resistance linked to higher risk of endometrial neoplasia in PCOS-IR patients.
Model achieved moderate discrimination (AUC = 0.767) with high sensitivity (0.913).
Key predictive markers include age, HDL-C, FAI, and HOMA-IR.
Guideline-Based Recommendations
Diagnosis
Utilize ultrasound and histopathology for diagnosis of endometrial polyps.
Management
Consider risk stratification model for pre-hysteroscopy assessment.
Monitoring & Follow-up
Monitor metabolic parameters in PCOS-IR patients.
Risks
Increased risk of premalignant and malignant changes in endometrial polyps.
Patient & Prescribing Data
185 PCOS-IR patients with ultrasound-detected endometrial polyps.
Hysteroscopic polypectomy performed for definitive diagnosis.
Clinical Best Practices
Incorporate metabolic profiling in the assessment of PCOS-IR patients.
Use a multi-variable model for risk stratification in clinical settings.
